RT Journal Article
T1 Towards precision pain medicine for pain after cancer: the Cancer Pain Phenotyping Network multidisciplinary international guidelines for pain phenotyping using nociplastic pain criteria.
A1 Nijs, Jo
A1 Lahousse, Astrid
A1 Fernández-de-Las-Peñas, César
A1 Madeleine, Pascal
A1 Fontaine, Christel
A1 Nishigami, Tomohiko
A1 Desmedt, Christine
A1 Vanhoeij, Marian
A1 Mostaqim, Kenza
A1 Cuesta-Vargas, Antonio
A1 Kapreli, Eleni
A1 Bilika, Paraskevi
A1 Polli, Andrea
A1 Leysen, Laurence
A1 Elma, Ömer
A1 Roose, Eva
A1 Rheel, Emma
A1 Tümkaya Yılmaz, Sevilay
A1 Liesbet, De Baets
A1 Huysmans, Eva
A1 Turk, Ali
A1 Saraçoğlu, İsmail
K1 Dolor neoplásico
K1 Cáncer - Tratamiento
K1 Oncología
AB Pain after cancer remains underestimated and undertreated. Precision medicine is a recent concept that refers to the ability to classify patients into subgroups that differ in their susceptibility to, biology, or prognosis of a particular disease, or in their response to a specific treatment, and thus to tailor treatment to the individual patient characteristics. Applying this to pain after cancer, the ability to classify post-cancer pain into the three major pain phenotypes (i.e. nociceptive, neuropathic, and nociplastic pain) and tailor pain treatment accordingly, is an emerging issue. This is especially relevant because available evidence suggests that nociplastic pain is present in an important subgroup of those patients experiencing post-cancer pain. The 2021 International Association for the Study of Pain (IASP) clinical criteria and grading system for nociplastic pain account for the need to identify and correctly classify patients according to the pain phenotype early in their treatment. These criteria are an important step towards precision pain medicine with great potential for the field of clinical oncology. Within this framework, the Cancer Pain Phenotyping (CANPPHE) Network, an international and interdisciplinary group of oncology clinicians and researchers from seven countries, applied the 2021 IASP clinical criteria for nociplastic pain to the growing population of those experiencing post-cancer pain. A manual is provided to allow clinicians to differentiate between predominant nociceptive, neuropathic, or nociplastic pain after cancer.
PB Elsevier
YR 2023
FD 2023-05
LK https://hdl.handle.net/10630/35695
UL https://hdl.handle.net/10630/35695
LA eng
NO Jo Nijs, Astrid Lahousse, César Fernández-de-las-Peñas, Pascal Madeleine, Christel Fontaine, Tomohiko Nishigami, Christine Desmedt, Marian Vanhoeij, Kenza Mostaqim, Antonio I. Cuesta-Vargas, Eleni Kapreli, Paraskevi Bilika, Andrea Polli, Laurence Leysen, Ömer Elma, Eva Roose, Emma Rheel, Sevilay Tümkaya Yılmaz, Liesbet De Baets, Eva Huysmans, Ali Turk, İsmail Saraçoğlu, Towards precision pain medicine for pain after cancer: the Cancer Pain Phenotyping Network multidisciplinary international guidelines for pain phenotyping using nociplastic pain criteria, British Journal of Anaesthesia, Volume 130, Issue 5, 2023, Pages 611-621, ISSN 0007-0912, https://doi.org/10.1016/j.bja.2022.12.013
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 10 mar 2026